NASDAQ: BGNE
Last close prices updated as of
May 26, 2023, 6:52 PM EST
| USD | BATS BZX Real-Time Price
- Last Close 236.9
- Sector Healthcare
- Industry Biotechnology
- Investment Style Large Growth
- Day Range 228.16 – 238.48
- Year Range 124.46 – 279.12
- Market Cap 24.7661 Bil
- Volume / Avg 205,484.0 / 198,446.1
- Price / Sales 15.76
- Price / Book 5.96
- Forward Div Yield —
- Trailing Div Yield —
Morningstar‘s Stock Analysis BGNE
Valuation
Currency in —
Is it the right time to buy or sell?
Is it the right time to buy or sell?
1-Star Price
INVESTOR
5-Star Price
INVESTOR
Economic Moat
INVESTOR
About Quantitative Ratings
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Unlock Our Full Analysis With Morningstar Investor
Company Profile BGNE
Business Description
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.
Contact
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay
Grand Cayman, KY1-1108, CYM
Grand Cayman, KY1-1108, CYM
Related Articles BGNE
Competitors & Peers BGNE
Morningstar does not cover competitors or peers for this firm.
FAQs for BeiGene Ltd ADR Stock
No. BGNE does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
BGNE’s market cap is 24.77 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.
It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the
largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
BGNE’s stock style is Large Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns.
Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
BGNE’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare BGNE’s historical performance against its industry peers and the overall market.